Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice.
Open Access
- 12 March 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer and Metastasis Reviews
- Vol. 35 (1), 141-50
- https://doi.org/10.1007/s10555-016-9612-6
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2013
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospectsCancer Treatment Reviews, 2011
- Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapyAnnals Of Oncology, 2011
- Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European WorkshopJournal of Thoracic Oncology, 2010
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004